Damon Race: Pleased to Share GeneVentiv’s Scientific Debut at ASGCT 2026
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:
”We’re pleased to share GeneVentiv’s scientific debut at ASGCT 2026.
Our CSO, Paris Margaritis, DPhil, is presenting our work on a next-generation AAV8.FVa construct, advancing a differentiated approach to restoring thrombin generation in hemophilia A patients with or without inhibitors through native hepatic expression of a regulated coagulation cofactor.
The technology presented here forms part of GeneVentiv’s growing IP portfolio.
It’s exciting to reflect on this work as the foundation for our program, which has advanced to studies in hemophilia A canines.
We look forward to sharing additional data as development progresses.”
Stay updated with Hemostasis Today.
-
Sep 27, 2026, 07:57Christopher D: Personalized CRISPR Therapy and the Future of Rare Disease Care
-
Sep 27, 2026, 07:27Alexander Misono: Chronic Deep Vein Thrombosis and the Impact of Delayed Treatment
-
Sep 27, 2026, 07:17Emma Copperwaite: Back to BBTS With New Research and New Ideas
-
Sep 27, 2026, 05:58Alefiya B.: Imagine Treating a Genetic Disorder by Giving Cells the Instructions They are Missing
-
Sep 27, 2026, 04:5310 Posts Not to Miss This Week
-
Sep 27, 2026, 03:23Massimo Martino: VEN-DEC-GITMO – Advancing AML Treatment in Older Patients
-
Sep 27, 2026, 03:08Arrigo Francesco Giuseppe Cicero: Why Earlier LDL-C Lowering May Matter in Cardiovascular Prevention
-
Sep 27, 2026, 02:51Veronique Witko-Sarsat: Thromboinflammation at the 17th World Congress of Inflammation
-
Sep 27, 2026, 01:45Jin-Xiong She: Functional Iron Deficiency in the Setting of Chronic Inflammation